To evaluate the feasibility and the safety of applying chitosan membrane (ChiMe) on the neurovascular bundles (NVBs) after nerve-sparing robot-assisted radical prostatectomy (NS-RARP). The secondary aim of the study was to report preliminary data and in particular potency recovery data.
Introduction
Over recent decades, knowledge of peri-prostatic anatomical structures has increased in unison with the development of the radical prostatectomy (RP) surgical technique. Robotics has played a crucial role, especially with the advantage of magnification of anatomical structures. Nevertheless, even in the case of meticulous preservation of the peri-prostatic neurovascular bundles (NVBs) in patients undergoing robotassisted RP (RARP) there still remains a period of convalescence characterised by unrecovered potency [1] .
Such a delay in potency recovery is probably due to the surgical trauma to the anatomical structures and inflammatory responses from traction of the NVBs [2] . Indeed, physical traction of the NVBs can be minimised by a surgeon with extensive experience but cannot be fully eliminated during mobilisation of the prostate [3] .
Rather than await further innovations of the nerve-sparing (NS) technique, perhaps we should look for biological/ bioengineering solutions aimed at neuro-protection and neuro-regeneration [4] . Recently, Patel et al. [5] published their results on the placement of dehydrated human amnion/chorion membranes (dHACM) around the NVBs after NS-RARP, reporting an earlier return of continence and potency in the cohort that received the dHACM compared with the comparative cohort who did not receive the membranes. Thus, to contribute to the field, we began at our Centre our experience with chitosan in the form of membranes (ChiMe) applied on the NVBs after NS-RARP.
Chitosan has been widely used in a variety of biomedical applications, including peripheral nerve repair, due to its excellent biocompatibility, biodegradability, ready availability, and antibacterial properties. With these features chitosan is being used in periodontal and orthopaedic systems (either implantable or injectable), as a drug-delivery system, as a healing agent, as a pulmonary surfactant additive and, of specific interest, as a scaffold for regeneration of various tissues (nerve, skin, bone, cartilage) [6, 7] .
The primary endpoint of the present study was to evaluate the feasibility and safety of applying ChiMe on the NVBs after NS-RARP. The secondary endpoint was to report preliminary data and more particularly potency recovery data after NS-RARP with ChiMe applied on the NVBs.
Patients and Methods
The enrolment phase lasted from July 2015 to September 2016 and was conducted in accordance with Good Clinical Practice Rules and the ethical principles of the Declaration of Helsinki. The Institutional Review Board of the San Luigi Gonzaga Hospital (Orbassano, Italy) approved the study (80/ 2015).
Inclusion Criteria
All men aged 45-75 years, with a five-item version of the International Index of Erectile Function (IIEF-5) score of ≥17 [8] , referred to our Institution with prostate cancer (T1-2 N0 M0 clinically staged according to TNM staging [9] , regardless of prostate size) and to whom NS-RARP was proposed. All patients had preoperatively undergone prostate multiparametric MRI (mp-MRI) according to the European Society of Urogenital Radiology (ESUR) guidelines [10] .
Exclusion Criteria
Suspicious DRE, previous radiation therapy, hormonal therapy and/or previous prostate surgeries. Evidence at mp-MRI of extracapsular extension of the disease and/or seminal vesicle invasion [11] .
ChiMe Manufacture
Briefly, a 1.5% solution of chitosan (degree of acetylatioñ 5.5%) in 0.5% aqueous acetic acid was poured into plastic dishes, followed by drying at room temperature. The resulting films were treated with a solution of ammonia in methanol/ water, followed by intense washing with distilled water, and drying. A defined pattern of holes of~160 lm diameter was made using a perforator. These sheets (thickness~30 lm) were then cut into 4 9 3 cm membranes ( Fig. 1) , placed in sterilisation bags and sterilised using ethylene oxide.
Surgical Technique
RARP was performed as described previously [12] . Based on the clinical, histological, and radiological features of the disease, an intrafascial or interfascial NS technique with a lateral/postero-lateral approach was performed [13] . At the end of the total anatomical reconstruction [12] , the 4 9 3-cm ChiMe was cut into two rectangular pieces. When satisfactory haemostasis was achieved, one of the cut pieces was introduced by a Johann grasper through the assistant's port (Fig. 2 ) and then applied on the NVB by the first surgeon (Fig. 3) . The procedure was then repeated contra-laterally.
Functional Rehabilitation
All patients were administered a phosphodiesterase type 5 inhibitor (PDE5-i; tadalafil 20 mg twice/week) for 3 months after NS-RARP. Subsequently, PDE5-i was continued if required.
The following data were prospectively collected and registered in a dedicated database:
Demographic Data
Age, body mass index, PSA level, biopsy Gleason score, mp-MRI status and American Society of Anesthesiologists score. 
Intraoperative Data
Skin-to-skin operation time, estimated blood loss, complications, and transfusion rate.
Postoperative Data
Postoperative complications (as classified according to the Clavien-Dindo system [14] ) until 90 days after NS-RARP, catheterisation time, and hospital stay.
ChiMe Side-effects
Specifically for the purpose of the study, any sign/symptom of local allergy/intolerance to ChiMe (including itching and flushing) or anaphylaxis was recorded and evaluated. No specific tests were scheduled, as neither allergic reactions nor other side-effects to chitosan medical devices available on the market have been reported, even in patients with known shellfish allergy [15] .
Pathological Data
Prostate and tumour volume, pathological Gleason score, staging according to TNM staging system [9] and positive surgical margin (PSM) rate. Specimens were processed according to Gasparrini et al. [16] .
Oncological follow-up comprised PSA level measurements at 1, 3 and 6 months after NS-RARP. Biochemical recurrence after the intervention was defined as a PSA level of >0.2 ng/ mL.
Functional Data
Urinary continence evaluated at catheter removal and at 1, 3 and 6 months after NS-RARP. The question from the Expanded Prostatic Index Composite (EPIC) questionnaire: 'How many pads of adult diapers per day did you usually use to control leakage?' was used to define pre-and postoperative continence. Patients were defined as continent if they did not use any pads or used one safety pad/day [17] .
Erectile function
Preoperative erectile function was evaluated by the IIEF-5 [8] . Potency recovery with or without PDE5-i treatment was defined as an erection sufficient for intercourse or masturbation (score >2 at question two of the EPIC questionnaire) and assessed at 1, 3 and 6 months after NS-RARP.
Statistical Analysis
Means and standard deviations (SDs) were used to report continuous variables with normal distributions. For continuous variables that were skewed, medians and interquartile ranges (IQRs) were reported. Frequencies and proportions were used for categorical variables. Univariable and multivariable regression analyses were used to assess the effect of potential independent variables on potency recovery. P values < 0.05 were considered statistically significant. Statistical analyses were performed by Statistic 8 software (StatSoft, Tulsa, OK, USA). 
Results
In all, 140 patients underwent NS-RARP with ChiMe applied on the NVBs. The patients' demographics are reported in Table 1 . The median baseline IIEF-5 score was 24. Perioperative data are detailed in Table 2 . The ChiMe was easily applied in 131 cases and the median (IQR) time for applying the ChiMe was 10 (9-11) s/side. In nine cases one or both of the ChiMe had to be removed for a while: a dedicated suture was performed to control the bleeding occurring from the NVB and then the ChiMe was re-applied. Complications are detailed in Table 3 .
No patients reported any sign of intolerance/allergy attributable to the ChiMe. Pathological data are reported in Table 4 . The overall potency rate was 32.8%, 54.2% and 68.6% at 1, 3 and 6 months postoperatively, respectively. Potency rates after stratification according to degree of NS are detailed in Table 5 . Univariable regression analysis for potency (Table 6 ) revealed age as independent factor (P = 0.022) at 3-months postoperatively and hypertension at 6-months postoperatively (P = 0.008). Age was also confirmed as independent factor at 3-months postoperatively in the multivariable analysis (b À0.20; 95% CI À0.40 to 0.04, P = 0.015).
Discussion
Peripheral nerve recovery after trauma is dependent on the severity of the damage. Spontaneous recovery is possible, if the continuity of the nerve is maintained, as in the case of neuroapraxia. In cases of complete nerve transection (axonotmesis/neurotmesis), a surgical intervention is required to restore the continuity of the nerve. Autologous nerve grafts (auto-grafts) would be the 'gold standard' technique for repairing peripheral nerve defects, where a healthy nerve fragment of sensory origin would be used to bridge the gap [3] . However, this practice presents some disadvantages: it requires an additional incision for removing the healthy sensory nerve, leading to a residual sensory deficit; also, graft material is limited especially in the case of an extended nerve lesion. As an alternative to auto-grafting, various biomaterials have been developed for nerve reconstruction [18] . In particular, chitosan, as a natural polysaccharide, has recently attracted increasing attention due to its good biocompatibility, biodegradability, non-toxicity, ready availability, and physicochemical properties [4, 6, 7, [18] [19] [20] [21] [22] . Indeed, chitosan has been used in a variety of biomedical applications, including peripheral nerve repair. The use of a chitosan-based nerve tube has already been authorised and Conformit e Europ eene (CE)-certified (Reaxon â Nerve Guide, Medovent, Germany).
Recent in vitro studies have shown the suitability of ChiMe as a substrate for survival and oriented Schwann cell growth LND, lymph-node dissection. [18] , as well as survival and differentiation of neuronal cells [19] . Chitosan-based scaffolds have been widely used for neural repair in different animal models [20] . Chitosan-based nerve conduits, alone or combined with other biomaterials, have been found to effectively bridge peripheral nerve defects [7, 21] . Consistent enhancement of functional and morphological nerve regeneration has been demonstrated [22] . The problem with prostate surgery is that it is not 'onenerve-only' damage: the anatomy of the neuronal structures surrounding the prostate is complex, neuronal fibres are autonomic and it is impossible to identify single fibres to be reconstructed. Moreover, the complex mix of injuries, ranging from stretching and electro-cautery damage to transection, impact on the integrity of NVB during surgery.
Nevertheless, previous attempts have been made to transfer the concept of sural nerve grafting to RP, but with no significant results [23] . In parallel with such attempts, NS techniques have improved considerably, reaching their acme with the advent of robotics [24, 25] . Moreover, some authors have proposed helpful ways of maximising NS during RARP: to name a couple of them, Tewari et al. [26] described a nerve stretching monitor and Finley et al. [27] tried regional hypothermia using a rectal cooling balloon. But the urological community is still awaiting more consistent innovations.
The use of growth factors and anti-inflammatory substances for prostatic NVB regeneration has been proposed. Specifically, Patel et al. [5] described the use of dHACM, as a source of implantable neurotrophic factors and cytokines. They applied the dHACM in 58 patients who underwent full NS-RARP. Patients were matched with a similar group of patients who did not receive the dHACM. They reported a faster return of potency, with a higher rate of potent patients at 2 months in the dHACM-grafted group (65.5% vs 51.7%). There may be some concern about the use of these kinds of membranes, as they are applied close to the previous tumour site. However, we will need to await longer oncological follow-up data to draw definitive conclusions.
In the present study, we investigated the feasibility of using ChiMe as an inert scaffold for neural regeneration. Following the encouraging results of chitosan cylinders in promoting somatic nerve re-growth, we felt that chitosan might *Continence was defined using a single question from the EPIC questionnaire: 'How many pads of adult diapers per day did you usually use to control leakage?' Patients were defined as continent if they did not use any pads or used one safety pad/day. †Potency was defined as an erection sufficient for intercourse or masturbation (score >2 at question number two of EPIC questionnaire) with or without PDE5-i treatment. overcome any neural deficits resulting from the surgical insult to the NVBs during NS-RARP. The characteristics of the chitosan that we thought would be useful were: i) the neuroprotective/neuroregenerative effect [7] , ii) the antitumoral activity [28] , iii) the anti-inflammatory and analgesic effect [29] , iv) the haemostatic activity (chitosan is an haemostatic agent approved in the USA and in Europe, used by the American Marine Corps, and in pre-clinical studies has been reported to be essential in the survival of pigs with otherwise lethal arterial lesions [30] ), and v) Antimicrobial activity [31] . Moreover, we were encouraged by the results obtained in our institutional in vitro studies with autonomic nerves (they will be object for future publications in dedicated journals).
Nevertheless, due to the anatomy of the prostatic NVBs, we had to devise a suitable form of the biomaterial. Consequently, it was produced in form of a thin square, with micro holes. This form was used pre-CE mark certification and thus why the study was submitted to and approved by our Institutional Review Board and notified to the relevant body. Applying ChiMe on the NVBs was easy and safe in almost all the patients. After this preliminary experience, it became apparent that bleeding from the NVB has to be well controlled before placing the ChiMe. It is not necessary for the ChiMe to perfectly adhere to the NVB, but rather that it should just be deposited on the NVB, allowing it to work as a scaffold for neural regeneration.
After applying ChiMe in 140 patients, we did not record any complications or adverse events. Moreover, the length of the operative time was not significantly affected with respect to the standard procedure. For functional outcomes, in the present study, we preliminary reported potency data after applying ChiMe on the NVBs after NS-RARP, which were satisfactory with a trend towards a faster recovery of erectile function with respect to our previous experience, although no definitive conclusions can be drawn as no control arm was included in this pre-CE mark study. Having said this, confirming previous literature findings, age was found to be the most significant predictor of postoperative potency recovery, even in a selected cohort of patients with high preoperative potency as assessed by IIEF-5 score [32] .
No adverse events were recorded but two fevers, which were reasonably attributed to infection, were successfully managed by antibiotics.
A frequent question about chitosan-based medical products is whether they are able to induce allergic reactions in patients known to have shellfish allergy. To the best of our knowledge, there have been no allergic reactions to chitosan medical devices. There have been sporadic reports of cases of allergic reactions to nonmedical products, e.g. dietary supplements and cosmetics that contain chitosan; however, in these cases a causal relationship with the chitosan ingredient is not clear.
The chitosan used for the production of the ChiMe was prepared in multiple controlled processing steps where the starting material is chitin from Pandalus borealis, which is processed under defined conditions. Chitin is freed of proteins and minerals by treatments with dilute alkaline and acidic solutions, and then converted to chitosan by hydrolysis for several hours and at high temperatures. These hydrolysis conditions cause a denaturation and destruction of proteins and nucleic acids, so that allergic reactions to such treated chitosan can be excluded even in patients with known shellfish allergy who previously had anaphylactic reactions when in contact with shellfish [15] .
Our present study was not devoid of limitations; it was an observational study with prospective collection of data but no comparative cohort was included. This would have added value to the study but the present paper reported the phase II study pre-CE mark achievement. Designing a study including a control arm was beyond the aims of the present study. A multicentre randomised study after CE-mark achievement would be more representative of the real life situation, eliminating the bias of the single surgeon/single NS technique that occurs in a single-centre study.
The best candidates for receiving the membrane have yet to be investigated. Indeed, the effect of the ChiMe can be both neuro-protective and neuro-regenerative. We assume that in patients who undergo bilateral intrafascial NS, where there is no loss of neural tissue that these patients would benefit from the neuro-protective property of the ChiMe. Conversely, we would expect a more substantial contribution in accelerating potency recovery in patients who undergo partial NS techniques (with loss of neural tissue), as in this cohort the neuro-regenerative effect of the ChiMe would be the key point.
For factors influencing potency recovery, radiation therapy could affect longer follow-up data. The 6-month follow-up did not reveal a negative impact on potency recovery, as the treatment was started from the fifth postoperative month in all the patients who required it. Moreover, long-term oncological data are being recorded, and longer follow-up is required to evaluate future outcomes for our present cohort.
In summary, in our experience applying ChiMe on the NVBs after NS-RARP was feasible and safe, without compromising the length, difficulty or the complication rate of the 'standard' procedure. No patients had signs of intolerance/allergy attributable to the ChiMe. Potency recovery data were encouraging, even if no definitive conclusions can be drawn about the effect of the ChiMe. After the confirmation of the absence of adverse events and CE-mark certification, an adequately powered, prospective randomised trial of applying ChiMe on the prostatic NVB after NS-RARP will be designed to the test its influence on potency recovery.
